SynthesisJournal of veterinary internal medicine
The immunotherapy of canine osteosarcoma: a historical and systematic review.
Synthesis in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 73 citations in OpenAlex.
- The tumor microenvironment of metastatic osteosarcoma in the human and canine lung.Communications biology · 2025Review
- Myeloid Cells in the Immunosuppressive Microenvironment as Immunotargets in Osteosarcoma.ImmunoTargets and therapy · 2025Review
- Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans.Communications biology · 2023Article
- Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.Veterinary sciences · 2023Review
- Investigating cell death responses associated with histotripsy ablation of canine osteosarcoma.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2023Article
- Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.PloS one · 2023Article
- Nanocarriers in Veterinary Medicine: A Challenge for Improving Osteosarcoma Conventional Treatments.Nanomaterials (Basel, Switzerland) · 2022Review
- Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma.BMC medical genomics · 2022Article
- Osteosarcoma Cell-Derived Exosomal ELFN1-AS1 Mediates Macrophage M2 PolarizationFrontiers in oncology · 2022Article
- Long Noncoding RNA LINC00467: Role in Various Human Cancers.Frontiers in genetics · 2022Review
- Abnormal Function of Circulating Follicular Helper T Cells Leads to Different Manifestations of B Cell Maturation and Differentiation in Patients with Osteosarcoma.Journal of healthcare engineering · 2022Article
- Digital Lesions in Dogs: A Statistical Breed Analysis of 2912 Cases.Veterinary sciences · 2021Article
- Enhanced Cytotoxic Effect of Doxorubicin Conjugated to Glutathione-Stabilized Gold Nanoparticles in Canine Osteosarcoma-In Vitro Studies.Molecules (Basel, Switzerland) · 2021Article
- Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- The effect of miR-539 regulating TRIAP1 on the apoptosis, proliferation, migration and invasion of osteosarcoma cells.Cancer cell international · 2021Article
- LINC00467 facilitates osteosarcoma progression by sponging miR‑217 to regulate KPNA4 expression.International journal of molecular medicine · 2021Article
- Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector.Veterinary and comparative oncology · 2021Article
- Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.Frontiers in oncology · 2021Review
- Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.Journal of veterinary internal medicine · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in humans. Despite dose intensification with conventional cytotoxic therapies, survival times for dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, with the principal cause of mortality being the development of pulmonary metastases. Given the therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is clinically justified. Evidence suggests that osteosarcoma is an immunogenic tumor, and development of immunotherapies for the treatment of microscopic lung metastases might improve long-term outcomes. In this review, the history and foundational knowledge of immune interactions to canine osteosarcoma are highlighted. In parallel, immunotherapeutic strategies that have been explored for the treatment of canine osteosarcoma are summarized. With a greater understanding and awareness for how the immune system might be redirected toward combating osteosarcoma metastases, the rational development of diverse immune strategies for managing osteosarcoma holds substantial promise for transforming the therapeutic landscape and improving disease management in both dogs and human beings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.